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S U M M A R Y
Objective: The aim of the present study was to determine whether hepatitis C virus (HCV) RNA present at
week 12 is a good predictor of the response to interferon (IFN) monotherapy in hemodialysis patients
with hepatitis C.
Methods: Hemodialysis patients with hepatitis C who were treated between 1997 and 2008 with IFN
monotherapy for 48 weeks without dose reduction were included. The predictive value of HCV RNA at
week 12 for achieving a sustained virological response (SVR) was determined.
Results: Forty patients (mean age 47  9 years; 75% males and 80% with genotype 1) were included. Septal
ﬁbrosis or cirrhosis was observed in 38% of these patients. Twelve (30%) of the 40 patients achieved SVR. HCV
RNA was undetectable at week 12 in 68%. The positive predictive value of HCV RNA at week 12 was 45% and
the negative predictive value was 100%.
Conclusions: The presence of HCV RNA at week 12 had a high negative predictive value for SVR in
hemodialysis patients with chronic hepatitis C treated with IFN for 48 weeks. Therefore, if HCV RNA is
detected at week 12, treatment should be discontinued due to the low probability of a sustained
response.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Although the adoption of universal precaution methods has
reduced the transmission of hepatitis C virus (HCV) among
hemodialysis patients,1 the prevalence of this infection has
remained high in these patients compared to the general
population. The prevalence of HCV infection also varies according
to geographic region; the rates are less than 5% in northern
European countries,2 approximately 8% in the USA,3 and as high as
70% in Saudi Arabia.4 In addition, the prevalence of this infection
varies widely between dialysis centers in the same country.
In Brazil, the Brazilian Society of Nephrology has conducted an
annual census of patients on dialysis therapy since the beginning of
this century. Data from the 2010 census, recently reported,5 show
that 340 of the 638 active dialysis centers answered the survey
questions and information was obtained for 49 077 patients of the
92 091 estimated total number of patients on dialysis in the
country. The prevalence of HCV infection among dialysis units was* Corresponding author. Tel.: +55 17 3121 6965.
E-mail address: patriciafucuta@gmail.com (P.d.S. Fucuta Pereira).
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http://dx.doi.org/10.1016/j.ijid.2012.09.0015.8%, and fortunately it has been declining – the prevalence was
19.9% in 1999.6
The treatment of HCV in patients under renal replacement
therapy is of critical importance. The impact of chronic hepatitis C
infection in these patients is high, as recent observations have
documented a greater probability of death due to liver cirrhosis,
hepatocarcinoma, and cardiovascular disease in dialysis patients
infected with HCV compared to uninfected subjects.7,8 Further-
more, a large cohort study that compared the frequency of cancer
among dialysis patients to that of the general population found a
higher overall risk for cancer in these patients, which included the
risk of liver cancer attributable to exposure to hepatitis B and C
viruses.9 Severe post-transplant complications of HCV infection,
such as glomerulopathies, loss of renal grafts,10,11 and a reduced
10- and 20-year survival rate,12,13 have been demonstrated in
HCV-positive kidney transplanted patients. In addition, kidney
transplanted patients with hepatitis C showed higher morbidity
and mortality due to liver disease than did immunocompetent
patients with hepatitis C.14
As the post-transplant administration of interferon (IFN) has
been associated with the risk of renal graft loss,15–17 its
administration is generally not recommended.18 Instead, all efforts
should be made to eradicate the infection before renal transplant.ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Baseline demographic and clinical characteristics of the study patients (n = 40)
Characteristics
Age, years, mean  SD 47  9
Male gender, n (%) 30 (75)
Hemodialysis/peritoneal dialysis, n 38/2
Time on dialysis, years, median (IQR) 6 (4–7)
Previous kidney transplant, n (%) 11 (28)
Etiology of kidney disease, n (%)
Hypertension 14 (35)
Glomerulonephritis 3 (8)
Diabetes mellitus 2 (5)
Other/unknown 21 (52)
Duration of HCV infection, years, median (IQR) 8 (6–14)
HCV genotype, n (%)
Type 1 21 (80)
Type 2 1 (4)
Type 3 2 (8)
Type 4 1 (4)
Type 5 1 (4)
Liver histology, n (%)
Bridging ﬁbrosis or cirrhosis 15 (38)
ALT ( ULN), median (IQR) 1.02 (0.62–1.63)
Hemoglobin (g/dl), mean  SD 12  1.5
Platelet count ( 109/l) 183.025  72.318
ALT, alanine aminotransferase; HCV, hepatitis C virus; IQR, interquartile range; SD,
standard deviation; ULN, upper limit of normal.
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virological response (SVR; i.e., no detectable HCV RNA at 24 weeks
after cessation of therapy) rate for hemodialysis patients who
received conventional IFN monotherapy was 39%, which was
greater than that estimated for immunocompetent patients.
However, the low tolerance of these patients to IFN may lead to
high rates of treatment discontinuation.20 Despite the large
number of studies evaluating the predictive value of HCV RNA
during the early stages of treatment (weeks 4 to 12) for a sustained
response in non-uremic patients,21,22 this parameter has not been
established in hemodialysis patients. This analysis would be useful
because of the low tolerance of these patients to treatment.
The objective of the present study was to evaluate the
predictive value of HCV RNA at week 12 in dialysis patients
treated with conventional IFN for 48 weeks.
2. Methods
2.1. Patients
A retrospective study was conducted on hemodialysis patients
with chronic hepatitis C (anti-HCV reactive and HCV RNA-positive)
who were attended at the Hepatitis Unit of the Federal University
of Sa˜o Paulo between 1997 and 2008. Patients treated with
conventional IFN monotherapy for 48 weeks and who had HCV
RNA tests at week 12 of treatment and at week 24 post-treatment
were selected for this study.
Patients infected with HIV and/or hepatitis B virus and those
previously treated for hepatitis C or who had their treatment
discontinued were excluded.
The study was approved by the local ethics committee and was
conducted in accordance with the Declaration of Helsinki.
2.2. Variables analyzed and determination of HCV RNA
The following variables were analyzed: gender, age, etiology of
chronic renal disease, type of dialysis, history of kidney transplan-
tation, time on dialysis, estimated duration of infection, alanine
aminotransferase (ALT) level, stage of hepatic ﬁbrosis, HCV
genotype, and the presence of HCV RNA at week 12 of treatment
and at week 24 post-treatment. The duration of infection was
estimated based on the ﬁrst year of dialysis or the year of the ﬁrst
blood transfusion if before 1992.
The HCV RNA content of stored serum samples (freezer
temperature 20 8C) was determined by qualitative PCR (Cobas
Amplicor HCV Test, Roche Diagnostic Systems, USA) using a
detection limit of 50 IU/ml. The HCV genotype was determined by
sequencing of the 50-untranslated region.23
2.3. Therapeutic regimen
Treatment was indicated for patients whose liver biopsies
showed interface hepatitis and/or the presence of stage 2 ﬁbrosis,
according to the Metavir classiﬁcation.24 The therapeutic regimen
consisted of conventional IFN alpha-2a or IFN alpha-2b
(3 000 000 IU, three times per week) for 48 weeks, which in all
cases was administered following dialysis sessions.
2.4. Evaluation of virological response
An early virological response (EVR) to antiviral treatment is
usually deﬁned as partial (pEVR) when a 100-fold decrease in
viral load occurs at week 12, and as complete (cEVR) when HCV
RNA at week 12 is undetectable. In the present study the EVR was
evaluated by qualitative HCV RNA level at week 12 (cEVR).
Qualitative determination of HCV RNA 24 weeks after therapy wasused for analysis of SVR. Per-protocol analysis was used to
determine the response rate.
2.5. Statistical analysis
A descriptive analysis of the variables of interest was performed
and the association between variables was determined. When
indicated, categorical variables were compared using Fisher’s exact
test. The positive and negative predictive values of HCV RNA at
week 12 for SVR were calculated. A level of signiﬁcance of <0.05
was used. PASW 18.0 software (SPSS, Inc., Chicago, IL, USA) was
used for the statistical analysis.
3. Results
A total of 113 patients were treated during the study period and
40 of these fulﬁlled the inclusion criteria. The other 73 patients
were excluded from the study due to an early interruption/
abandonment of treatment or a dose reduction in 31 patients
(42%), the absence of serum for analysis at week 12 in 24 patients
(33%), and the presence of HBV co-infection in 18 patients (25%).
There was no difference between excluded and included patients
regarding age, time on dialysis, stage of ﬁbrosis, or genotype
distribution.
The mean age of the 40 patients included in the study was
47  9 years, and the majority of patients were male (75%). The time
on dialysis ranged from 1 to 19 years (median of 6 years), and the
main cause of known chronic renal disease was systemic arterial
hypertension.
According to the Metavir classiﬁcation for the staging of hepatic
ﬁbrosis on biopsy, it was absent in 5% of patients (stage 0), 57%
patients had stage 1, 15% had stage 2, 13% had stage 3, and 10% had
stage 4. The pretreatment epidemiological, clinical, and laboratory
characteristics of the patients are shown in Table 1.
3.1. HCV RNA at week 12 and the sustained virological response
HCV RNA was undetectable at week 12 in 27 patients (68%), and
the overall SVR rate was 30% (12/40). According to HCV genotyping
performed in 26 patients, SVR was 24% in genotype 1, and the only
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genotype 2, two genotype 3, one genotype 4, and one genotype 5).
Forty-ﬁve percent of patients with negative HCV RNA at week
12 achieved SVR. However, none of the patients with detectable
HCV RNA at week 12 had SVR (p = 0.004), as shown in Figure 1. Thus
the cEVR had a negative predictive value (NPV) of 100% and a
positive predictive value (PPV) of 45%.
4. Discussion
This study showed that detectable HCV RNA at week 12 of
treatment had a high NPV (100%) for SVR in dialysis patients with
chronic hepatitis C given conventional IFN monotherapy for 48
weeks. HCV RNA was evaluated qualitatively at week 12, as this is
the conventional strategy used to evaluate the early response to
IFN monotherapy.25 This analysis is important because hepatitis C
dialysis patients require a special therapeutic approach. The
consequences of chronic HCV infection in this population, which
include decreased survival during the post-transplant period,
enforce the need to eradicate the virus. However, prolonged
therapy can cause severe side effects and can negatively impact the
stability of these patients.
The low tolerance of patients with renal failure to hepatitis C
treatment has been established and may be due to the greater
bioavailability of the drug or associations with co-morbid-
ities.20,26–28 In the study by Rocha et al.,20 mild to moderate side
effects of IFN therapy were observed in almost all patients and
included ﬂu-like symptoms, bone marrow suppression, diarrhea,
depression, dermatological alterations such as hair loss and
itching, infections, and hypothyroidism. Furthermore, severe side
effects that resulted in the discontinuation of treatment were seen
in 24% of the patients. Severe side effects were also the cause of
early treatment interruption in 19 of 37 hemodialysis patients
treated with conventional IFN therapy.26
The six meta-analyses regarding the efﬁcacy and tolerance of
IFN treatment in dialysis patients with chronic hepatitis C conﬁrm
the low tolerance of this population. In early 2000, two of these
studies29,30 demonstrated a high rate of treatment discontinuation
due to side effects (30% and 17%, respectively). These data were
later conﬁrmed by further meta-analyses conducted by Fabrizi
et al.19 and Gordon et al.31 that reported dropout rates of 19% and
26%, respectively. In the most recent meta-analyses by Alavian and
Tabatabaei32 and Fabrizi et al.,33 there were dropout rates of 29.7%
and 23%, respectively, following peginterferon therapy.Figure 1. Sustained virological response (SVR) rates according to HCV RNA at week
12 of antiviral treatment with interferon (IFN).Despite major advances in the treatment of chronic hepatitis C
in the last decade, approximately a half of immunocompetent
patients do not achieve sustained elimination of the virus with the
current recommended therapeutic regimen (peginterferon and
ribavirin).34 Furthermore, this proportion is even greater (about
60%) among dialysis patients given pegylated or conventional IFN
monotherapy.19
The factors associated with a positive response to antiviral
treatment have been extensively studied in patients with normal
renal function and include HCV genotype, stage of hepatic ﬁbrosis,
race, presence of steatosis/insulin resistance,35–39 treatment
compliance, ribavirin dose,40,41 and viral kinetics.35
Over the last decade, studies have established the probability of
a response to IFN treatment according to the kinetics of the HCV
RNA level during therapy. For example, patients who did not
achieve an EVR did not achieve SVR in 97% and 100% of cases,21,22
which conferred a high negative predictive value to the presence of
HCV RNA at week 12. The results from these studies favor the
discontinuation of treatment in patients who do not achieve EVR at
week 12 of treatment.
In regards of hemodialysis patients, Gordon et al.31 showed that
patients with lower rates of bridging ﬁbrosis or cirrhosis, lower
serum baseline HCV RNA levels, and infections with genotype non-
1 tended to achieve higher SVR rates, although these ﬁndings did
not reach statistical signiﬁcance. However, that study included
only baseline variables and did not allow for the interruption of
treatment in patients with a lower likelihood of response.
Therefore, the identiﬁcation of HCV RNA during treatment is a
highly attractive tool for the early identiﬁcation of patients with a
lower probability of response. Furthermore, this would indicate
when therapy should be interrupted in this population in which
the tolerance to treatment is signiﬁcantly lower.
Studies on the kinetics of HCV RNA as a predictor of SVR in
dialysis patients are scarce and have involved small numbers of
patients. In addition, many studies are not comparable because
they have evaluated different treatment regimens and HCV RNA at
different periods. Furthermore, these studies have included
patients with dose reductions and/or early treatment interruption,
which can impair the analysis of the relationship between viral
kinetics and SVR. Liu et al.42 reported treatment failure in all
patients who did not achieve a rapid virological response
(undetectable HCV RNA at week 4 of treatment). In that study
the patients received conventional or pegylated IFN monotherapy
for 24 weeks. In another study that evaluated 37 hemodialysis
patients,26 conventional IFN monotherapy for 48 weeks was
ineffective at inducing SVR in patients who had detectable HCV
RNA in the second month of treatment. Finally, a study of only 12
patients showed that the SVR rate was inﬂuenced by the clearance
of virus within the ﬁrst 2 months of treatment.43 Although
insufﬁcient to draw deﬁnitive conclusions, all these studies
suggest that HCV RNA kinetics have a high predictive value for
SVR. A recent meta-analysis by Gordon et al.44 supports these data,
as an association between SVR and viral negativity any time in the
ﬁrst 3 months of treatment was demonstrated.
The present study evaluated the predictive value of HCV RNA at
week 12 of conventional IFN treatment in 40 dialysis patients. This
group of patients was carefully selected from 113 dialysis patients
treated for hepatitis C and included only patients treated for 48
weeks without dose reduction. Therefore, this study contributes
data towards this unresolved issue. As we observed an NPV of
100%, these data show that the lack of cEVR is a strong indicator for
the failure of IFN therapy in dialysis patients.
All patients received 48 weeks of treatment irrespective of HCV
genotyping. The relationship between HCV genotype and treat-
ment response in this special population has not yet been well
established. In 2008 the Kidney Disease Improving Global
P.S. Fucuta Pereira et al. / International Journal of Infectious Diseases 17 (2013) e50–e53 e53Outcomes (KDIGO) working group published guidelines with
recommendations for the length of therapy based on HCV
genotype (48 weeks for genotypes 1 and 4, and 24 weeks for
genotypes 2 and 3) that were made by extrapolating data from the
general population;45 however these recommendations were not
based on randomized clinical trials. In this context it is also very
important to evaluate the predictive value of HCV RNA during very
early weeks of treatment for patients with HCV receiving antiviral
therapy for 24 weeks only.
The results of this study are meaningful due to the large number
of co-morbidities and the high rate of potentially severe side
effects of IFN treatment in this group of patients. Furthermore
determining stopping rules for hemodialysis patients is extremely
important for kidney transplant candidates because transplanta-
tion is delayed during IFN treatment. In conclusion, interruption of
treatment should be indicated for hemodialysis patients with
chronic hepatitis C on conventional IFN monotherapy who do not
achieve a cEVR, due to the low probability of a response after 48
weeks.
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